Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Spirax says tariff uncertainty affecting customer decisions

(Sharecast News) - Manufacturing group Spirax delivered a cautious outlook on Wednesday, saying that the uncertainty caused by trade tariffs is impacting customers' capital investment decisions. The company, which specialises in thermal energy and fluid technology solutions, said it delivered low single-digit organic growth in revenues in the first quarter.

That was despite lower demand for large projects in Steam Thermal Solutions (STS), particularly in China and South Korea - which accounted fore more than a fifth of STS revenues in 2024 - where conditions remain "challenging".

However, adjusted operating profit margins were slightly lower due to customers' phasing of some order shipment dates to later into the year.

Looking ahead to the rest of 2025, Spirax said it was keeping its outlook "while recognising that the evolving broader macroeconomic impact of tariffs remains uncertain".

"Our local manufacturing mitigates the direct exposure of tariffs and we expect to manage the financial impacts through surcharges, pricing and limited reorganisation of manufacturing activity," the company said.

Revenues growth and adjusted operating margins are expected to rise in the second half, as lower demand for large projects in STS is offset by growth elsewhere.

Shares were down 4.8% at 6,270p by 0827 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.